Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Renato V. La Rocca"'
Autor:
Mario E. Lacouture, Milan J. Anadkat, Matthew T. Ballo, Fabio Iwamoto, Suriya A. Jeyapalan, Renato V. La Rocca, Margaret Schwartz, Jennifer N. Serventi, Martin Glas
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Importance: Tumor Treating Fields (TTFields) are an anti-mitotic treatment approved for treating newly diagnosed and recurrent glioblastoma, and mesothelioma. TTFields in glioblastoma comprise alternating electric fields (200 kHz) delivered continuou
Externí odkaz:
https://doaj.org/article/1407100aef504fafbb08d1675907206e
Autor:
Shervin R. Dashti, Robert J. Kadner, Bradley S. Folley, Jason P. Sheehan, Dong Y. Han, Richard J. Kryscio, Mary B. Carter, Lisa B. E. Shields, Brian M. Plato, Renato V. La Rocca, Aaron C. Spalding, Tom L. Yao, Justin F. Fraser
Publikováno v:
Journal of neurosurgery. 137(6)
OBJECTIVE There is an unmet need for safe and rapidly effective therapies for refractory brain radiation necrosis (RN). The aim of this prospective single-arm phase II trial was to evaluate the safety and efficacy of a single low-dose targeted bevaci
Autor:
Lisa B. E. Shields, Aaron C Spalding, Dong Y. Han, Richard J. Kryscio, Brian M. Plato, Shervin R. Dashti, Jason P Sheehan, Justin F. Fraser, Mary B Carter, Renato V. La Rocca, Tom L. Yao, Robert J Kadner, Bradley S Folley
Publikováno v:
Archives of Clinical Neuropsychology. 36:1127-1128
Objective Evaluate neurocognitive change after single low-dose targeted intra-arterial (IA) bevacizumab in patients with brain radiation necrosis. Methods Phase II, single-arm, prospective trial. 10 adults underwent targeted 2.5 mg/kg IA bevacizumab.
Autor:
Kaylyn Sinicrope, Aaron C. Spalding, Lennea Coombs, Emily Sturgeon, David A. Sun, Mahan Ghiassi, Renato V. La Rocca
Publikováno v:
Neuro-Oncology Advances. 3:iii9-iii9
Leptomeningeal disease (LMD) is an aggressive late-stage event in cancer. It is rare in gynecological malignancies. We present a case of a patient diagnosed with cervical adenocarcinoma grade III, stage Ib1 who developed LMD treated with immunotherap
Autor:
Renato V La Rocca, Arash Rezazadeh
Publikováno v:
Expert Opinion on Pharmacotherapy. 12:1325-1332
Introduction: Carmustine-impregnated biodegradable wafers provide a locoregional adjunct to the treatment of patients with high-grade glial neoplasms. Their impact is that of delivering a chemotherapeutic agent directly to the tumor site at the time
Publikováno v:
Current Medical Research and Opinion. 25:149-160
Gliomas account for 42% of all primary CNS neoplasms and 77% of all malignant primary CNS neoplasms. Unfortunately the high-grade variant of gliomas, glioblastoma multiforme (GBM), is difficult to treat and generally considered incurable. Survival ra
Autor:
John Barstis, Ray Clark, David Rinaldi, Sreenivasa Nattam, Michael C. Perry, Chandra P. Belani, Glenn Mills, Renato V. La Rocca
Publikováno v:
Journal of Clinical Oncology. 21:2933-2939
Purpose: To explore the efficacy and safety of three regimens of weekly paclitaxel plus carboplatin as initial therapy and the feasibility of subsequent maintenance therapy versus observation in patients with advanced non–small-cell lung cancer (NS
Autor:
Carlos A. Jamis-Dow, Romano Danesi, W. Marston Linehan, M. Winnann Ewing, Michael R. Cooper, Charles E. Myers, Renato V. La Rocca
Publikováno v:
Journal of Urology. 145:393-398
Suramin, a polyanionic compound with known antiparasitic activity, has been shown to be adrenocorticolytic in primates and to have clinical efficacy in the treatment of patients with metastatic prostate cancer refractory to conventional hormonal mani
Autor:
M. W. Ewing, W. Marston Linehan, Renato V. La Rocca, Sue Liu, Patrick Anglard, Emile E. Trahan, Charles E. Myers
Publikováno v:
Journal of Urology. 145:389-392
Suramin, an antiparasitic agent which has been shown to block the stimulatory effect of growth factors on certain cancers, is currently being evaluated in clinical trials and as an antineoplastic agent in patients with advanced prostate carcinoma. Pr
Autor:
William Tester, Suresh S. Ramalingam, Chandra P. Belani, Preston S. Gable, Michael C. Perry, David Rinaldi, Renato V. La Rocca
Publikováno v:
Cancer. 113(3)
BACKGROUND. The purpose of this study was to compare the outcomes between elderly (aged ≥70 years) patients treated with paclitaxel on a weekly basis and with carboplatin (every 4 weeks) versus the standard 3-weekly regimen of carboplatin and pacli